Skip to main content
Mobile Main navigation
  • Expand Our Company
    • About Alnylam
    • Leadership
    • Diversity, Equity & Inclusion
    • Patient Access Philosophy
    • Corporate Responsibility
    • Transparency
    • Grants & Giving
    • Investigator Initiated Studies (IIS)
  • Expand Our Science
    • The Science of RNAi
    • Delivery Platforms
    • Therapeutic Areas
    • Pipeline
    • Clinical Trials
    • Scientific Advisory Board
    • Intellectual Property
    • Capella (Scientific Presentations)
  • Expand Our Products
    • Product Listing
  • Expand Our News
    • Newsroom
    • Press Releases
    • Capella (Scientific Presentations)
    • Media Kit
  • Expand Investors
    • For Investors
    • Stock Information
    • Investors Toolkit
    • Events & Presentations
    • Financial Information
    • SEC Filings
    • Corporate Governance
    • Analyst Coverage
    • Fundamentals
    • Ownership Profile
    • Annual Meetings
    • Press Releases
    • Capella (Scientific Presentations)
    • FAQs
  • Expand Medical Professionals
    • For Medical Professionals
    • Genetic Testing & Counseling
    • Early Access Program
    • Medical Publication Support
    • Investigator Initiated Studies (IIS)
  • Expand Patients
    • For Patients
    • Amyloidosis
    • Acute Hepatic Porphyria
    • Primary Hyperoxaluria
    • Patient Services
    • Genetic Testing and Counseling
    • Patient Advocacy
  • Expand Job Seekers
    • Careers
    • Working at Alnylam
    • Who We Are
    • Career Opportunities
    • Search Jobs
    • Diversity, Equity & Inclusion
  • Expand Quick Links
    • Clinical Trials
    • Corporate Responsibility
    • Diversity, Equity & Inclusion
    • Press Releases
    • Capella (Scientific Presentations)
    • Medical Resources (RNAi Science)
    • Contact Us
  • Follow Us:
  • youtube
  • facebook
  • X
  • linkedin
  • instagram
  • Our Company »
    • About Alnylam
    • Leadership
    • Diversity, Equity & Inclusion
    • Patient Access Philosophy
    • Corporate Responsibility
    • Transparency
    • Grants & Giving
    • Investigator Initiated Studies (IIS)
  • Our Science »
    • The Science of RNAi
    • Delivery Platforms
    • Therapeutic Areas
    • Pipeline
    • Clinical Trials
    • Scientific Advisory Board
    • Intellectual Property
    • Capella (Scientific Presentations)
  • Our Products »
    • Product Listing
  • Our News »
    • Newsroom
    • Press Releases
    • Capella (Scientific Presentations)
    • Media Kit
  • Investors »
    • For Investors
    • Stock Information
    • Investors Toolkit
    • Events & Presentations
    • Financial Information
    • SEC Filings
    • Corporate Governance
    • Analyst Coverage
    • Fundamentals
    • Ownership Profile
    • Annual Meetings
    • Press Releases
    • Capella (Scientific Presentations)
    • FAQs
  • Medical Professionals »
    • For Medical Professionals
    • Genetic Testing & Counseling
    • Early Access Program
    • Medical Publication Support
    • Investigator Initiated Studies (IIS)
  • Patients »
    • For Patients
    • Amyloidosis
    • Acute Hepatic Porphyria
    • Primary Hyperoxaluria
    • Patient Services
    • Genetic Testing and Counseling
    • Patient Advocacy
  • Job Seekers »
    • Careers
    • Working at Alnylam
    • Who We Are
    • Career Opportunities
    • Search Jobs
    • Diversity, Equity & Inclusion
  • Quick Links »
    • Clinical Trials
    • Corporate Responsibility
    • Diversity, Equity & Inclusion
    • Press Releases
    • Capella (Scientific Presentations)
    • Medical Resources (RNAi Science)
    • Contact Us
  • Follow Us:
  • youtube
  • facebook
  • X
  • linkedin
  • instagram
Home
search
language
Global
English
Austria
Deutsch
Belgium
Nederlands
Français
Brazil
Português
Canada
Français
English
Denmark
Dansk
France
Français
Germany
Deutsch
Ireland
English
Italy
Italiano
Japan
日本語
Luxembourg
Français
Deutsch
Netherlands
Nederlands
Portugal
Português
Spain
Español
Sweden
Svenska
Switzerland
Français
Deutsch
Italiano
Taiwan
繁體中文
United Kingdom
English
Home
  • Investors
    • For Investors
    • Stock Information
    • Investors Toolkit
    • Events & Presentations
    • Financial Information
    • SEC Filings
    • Corporate Governance
    • Analyst Coverage
    • Fundamentals
    • Ownership Profile
    • Annual Meetings
    • Press Releases
    • Capella (Scientific Presentations)
    • FAQs
  • Medical Professionals
    • For Medical Professionals
    • Genetic Testing & Counseling
    • Early Access Program
    • Medical Publication Support
    • Investigator Initiated Studies (IIS)
  • Patients
    • For Patients
    • Amyloidosis
    • Acute Hepatic Porphyria
    • Primary Hyperoxaluria
    • Patient Services
    • Genetic Testing and Counseling
    • Patient Advocacy
  • Job Seekers
    • Careers
    • Working at Alnylam
    • Who We Are
    • Career Opportunities
    • Search Jobs
    • Diversity, Equity & Inclusion
  • Quick Links
    • Clinical Trials
    • Corporate Responsibility
    • Diversity, Equity & Inclusion
    • Press Releases
    • Capella (Scientific Presentations)
    • Medical Resources (RNAi Science)
    • Contact Us
  • Follow Us
    • Youtube
    • Facebook
    • X
    • LinkedIn
    • Instagram
    • Sign Up
language
  • Our Company
    • About Alnylam
    • Leadership
    • Diversity, Equity & Inclusion
    • Patient Access Philosophy
    • Corporate Responsibility
    • Transparency
    • Grants & Giving
    • Investigator Initiated Studies (IIS)
  • Our Science
    • The Science of RNAi
    • Delivery Platforms
    • Therapeutic Areas
    • Pipeline
    • Clinical Trials
    • Scientific Advisory Board
    • Intellectual Property
    • Capella (Scientific Presentations)
  • Our Products
    • Product Listing
  • Our News
    • Newsroom
    • Press Releases
    • Capella (Scientific Presentations)
    • Media Kit
Global
English
Austria
Deutsch
Japan
日本語
Belgium
Nederlands
Français
Luxembourg
Français
Deutsch
Brazil
Português
Netherlands
Nederlands
Canada
Français
English
Portugal
Português
Spain
Español
Denmark
Dansk
Sweden
Svenska
France
Français
Switzerland
Français
Deutsch
Italiano
Germany
Deutsch
Taiwan
繁體中文
Ireland
English
United Kingdom
English
Italy
Italiano
Submitted by Anonymous (not verified) on Fri, 10/25/2019 - 15:11
Proxy Material Id
23636
Proxy Material Title
2019 Proxy Statement
Proxy Material Documents
Link
Proxy Material Link
https://clientapi.gcs-web.com/data/4273085b-1cd0-48e8-9d97-9b5b21faf122/assets/…
Proxy Material LastUpdated
Thu, 03/21/2019 - 15:06

FOLLOW US

Visit our social channels to learn more about the innovative work we are doing at Alnylam.

Footer First

  • Our Company
  • Our Science
  • Our Products
  • Our News

Footer Menu

  • Privacy Policy
  • Site Map
  • Legal Notice
  • Sign Up For Updates

Footer Second

  • Investors
  • Medical Professionals
  • Patients
  • Job Seekers

Footer third menu

  • Clinical Trials
  • Corporate Responsibility
  • Diversity, Equity & Inclusion
  • Press Releases
  • Capella
  • Medical Resources (RNAi Science)
  • Contact Us
  • Sign Up For Updates

Footer Fouth Menu

  • Privacy Policy
  • Media Kit
  • Legal Notice
  • Site Map

Copyright ©   Alnylam Pharmaceuticals, Inc. — All Rights Reserved